Nextbiomedical Co. Ltd. · KRX:389650

Nextbiomedical Co. Ltd. financial statements

Nextbiomedical Co. Ltd.'s income statement, balance sheet and cash flow, annual and quarterly, each figure dated and linked to the filing it was read from.

Financials

Annual, in KRW

Income statement

LineFY2025FY2024FY2023FY2022FY2021
Revenue16.5B9.54B4.88B2.80B2.27B
Cost of revenue4.95B3.72B2.77B2.51B2.89B
Gross profit11.5B5.82B2.11B284.5M-624.8M
Research and development7.58B6.62B4.78B3.58B3.25B
Selling, general and administrative1.60B2.70B2.47B2.37B1.29B
Operating income-719.5M1.52B-7.65B-4.86B-6.97B
Depreciation and amortization518.5M391.9M381.9M379.1M433.5M
EBITDA-201.0M1.91B-7.27B-4.48B-6.54B
Interest expense367.3M520.1M574.4M360.4M1.41B
Income before tax-311.1M2.86B-7.52B-5.73B-16.6B
Net income-311.1M2.86B-7.52B-5.73B-16.6B
Earnings per share, basic-38.28353.61-939.24-715.76-2,078.52

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021
Cash and equivalents6.79B308.0K262.0K491.0K22.0B
Short-term investments30.2B36.7B10.4B11.8B
Receivables2.24B1.85B1.03B389.1M118.7M
Inventory3.04B2.58B2.17B1.94B1.31B
Current assets43.3B46.9B18.0B17.5B23.7B
Property, plant and equipment11.3B11.4B11.7B
Total assets59.3B58.8B29.6B32.1B39.7B
Accounts payable47.7M13.4M58.2M45.0M4.10M
Current liabilities8.04B11.9B33.8B31.0B13.0B
Long-term debt950.7M763.5M933.5M500.0M
Total liabilities11.2B13.7B35.5B32.4B34.6B
Shareholders' equity48.1B45.2B-5.90B-253.8M5.08B
Shares outstanding8.13M8.09M8.01M8.01M8.01M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021
Cash from operations1.25B-1.20B-4.16B-8.21B-5.40B
Capital spending-3.15B-439.4M-64.5M-195.1M-774.2M
Free cash flow-1.90B-1.64B-4.22B-8.40B-6.17B
Cash from investing-26.4B4.11B-10.9B
Cash from financing28.3B973.6M95.2M
Share buybacks28.9B484.3M46.6M
Change in cash1.84B1.05B888.1M-19.0B15.3B